



November 4, 2024

JLK, Inc.
% Dave Yungvirt
CEO
Third Party Review Group, LLC
25 Independence Blvd
Warren, New Jersey 07059

Re: K242709

Trade/Device Name: JLK-PWI
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical image management and processing system
Regulatory Class: Class II
Product Code: LLZ
Dated: October 28, 2024
Received: October 29, 2024

Dear Dave Yungvirt:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of

Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system>.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical->

[devices/device-advice-comprehensive-regulatory-assistance](https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance)) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

A handwritten signature in black ink that reads "Jessica Lamb". The signature is written in a cursive style. Behind the signature, there is a faint, light blue watermark of the FDA logo.

Jessica Lamb, Ph.D.

Assistant Director

Imaging Software Team

DHT8B: Division of Radiological Imaging

Devices and Electronic Products

OHT8: Office of Radiological Health

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

Indications for Use

Submission Number (if known)

K242709

Device Name

JLK-PWI

Indications for Use (Describe)

JLK-PWI is an image processing software package to be used by trained professionals, including but not limited to physicians and medical technicians.

The software runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing, and analysis of Diffusion-weighted imaging (DWI) and Perfusion-weighted imaging (PWI) images for the brain from Magnetic Resonance Imaging (MRI) systems. Data and images are acquired through DICOM-compliant imaging devices. JLK-PWI provides both viewing and analysis capabilities for dynamic imaging datasets obtained through MRI protocols.

The DWI analysis capabilities are used to analyze local water diffusion properties from diffusion-weighted MRI data.

The PWI analysis capabilities are for analyzing dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculating parameters related to tissue flow (perfusion) and tissue blood volume.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



October 21, 2024

510(k) Summary

K242709

1. Contact Details (21 CFR 807.92(a)(1))

- Applicant Name: JLK, Inc.
- Applicant Address: JLK Tower, 5, Teheran-ro 33-gil Gangnam-gu Seoul n/a 06141 Korea, South
- Applicant Contact Telephone: (+82)1038507933
- Applicant Contact: Dr. Dongmin Kim
- Applicant Contact Email: dmkim@jlkgroup.com

- Correspondent Name: JLK, Inc.
- Correspondent Address: JLK Tower, 5, Teheran-ro 33-gil Gangnam-gu Seoul n/a 06141 Korea, South
- Correspondent Contact Telephone: (+82)1087641328
- Correspondent Contact: Dr. Jeeah Shin
- Correspondent Contact Email: jashin@jlkgroup.com

2. Device Name (21 CFR 807.92(a)(2))

Device Trade Name	JLK-PWI
Common Name	Medical image management and processing system
Classification Name	System, Image Processing, Radiological
Regulation Number	892.2050
Product Code(s)	LLZ

3. Legally Marketed Predicate Devices (21 CFR 807.92(a)(3))

Predicate #	Predicate Trade Name (Primary Predicate is listed first)	Product Code
K121447	iSchemaView RAPID	LLZ

4. Device Description Summary (21 CFR 807.92(a)(4))

JLK-PWI is image processing software designed to analyze Diffusion-weighted imaging (DWI) and Perfusion-weighted imaging (PWI) images from Magnetic Resonance Imaging (MRI) scanners. The software calculates local water diffusion properties from DWI images and the perfusion area, which is a delayed perfusion area, using the analyzed perfusion map from PWI images.

JLK-PWI can be used to communicate with a DICOM-compliant device or a PACS server to receive DWI and PWI images. The software is designed to automatically receive and analyze DWI and PWI images with DICOM image data. The analyzed diffusion and perfusion parameters, which are related to the tissue blood flow and volume, are written to the source DICOM and stored in the data storage. Medical professionals can review the analysis results through the implemented user interface (UI) or a connected PACS server.

5. Intended Use/Indications for Use (21 CFR 807.92(a)(5))

JLK-PWI is an image processing software package to be used by trained professionals, including but not limited to physicians and medical technicians.

The software runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing, and analysis of Diffusion-weighted imaging (DWI) and Perfusion-weighted



imaging (PWI) images for the brain from Magnetic Resonance Imaging (MRI) systems. Data and images are acquired through DICOM-compliant imaging devices.

JLK-PWI provides both viewing and analysis capabilities for dynamic imaging datasets obtained through MRI protocols.

The DWI analysis capabilities are used to analyze local water diffusion properties from diffusion-weighted MRI data.

The PWI analysis capabilities are for analyzing dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculating parameters related to tissue flow (perfusion) and tissue blood volume.

6. Indications for Use Comparison (21 CFR 807.92(a)(5))

JLK-PWI is an image processing software package that is substantially equivalent to iSchemaView Inc.'s RAPID (K121447), which is a previously cleared predicate device. Both devices share the same intended use, similar indications, technological characteristics, and principles of operation.

7. Technological Comparison (21 CFR 807.92(a)(6))

The proposed and predicate devices are brain DWI and PWI analysis tools designed to support trained professionals including but not limited to physicians and medical technicians. JLK-PWI integrates seamlessly with the hospital's MR equipment or PACS server, receiving DWI and PWI DICOM images and analyzing diffusion and perfusion parameters such as Apparent Diffusion Coefficient (ADC), Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), and Residue function time-to-peak (Tmax).

The proposed and predicate devices are equally intended for use as analysis tools in image processing for a MR perfusion study. Both devices run on standard physical and/or virtual servers installed within the hospital's network and protected by the firewall.

8. Non-Clinical and/or Clinical Tests Summary & Conclusions (21 CFR 807.92(b))

JLK, Inc. conducted extensive performance validation testing and software verification of the JLK-PWI system. This performance validation testing demonstrated that the JLK-PWI system accurately represents key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software. The documentation was provided as recommended by FDA's Guidance for Industry and FDA staff, "Content of Premarket Submissions for Device Software Functions," June 14, 2023.

JLK-PWI demonstrated reliable and accurate performance in calculating local water diffusion properties from DWI images and the perfusion area, which is a delayed perfusion area, using the analyzed perfusion map from PWI images. The software's results were substantially equivalent to those obtained using RAPID. These results indicate that JLK-PWI meets the predetermined performance criteria, validating its reliability and accuracy in analyzing DWI and PWI images.

In conclusion, JLK-PWI, which has the same intended use and exhibits substantially equivalent technological, safety, and performance characteristics, is substantially equivalent to the legally marketed predicate device, iSchemaView RAPID (K121447).